It was a smart play by the company to word document as such but the product has been available for some time and until it translates to positive revenues this is following a similar trend to many Bio-Pharma companies in which they pump stock up to hold a 7-10 day average well above the low, followed by a heavily reduced CR @ 20% below the moving average, to further continue research.
Until I hear revenue based announcements or see the SP slide back below 10c this is a sit on the sidelines play for me. Look at the 2014 pattern, this to me is going to follow a similar trend unless they can indicate some major deals, that is why Pharma is such a good industry to short (Valeant being a prime example).
GLTH though as I could be wrong and it is only my opinion.
- Forums
- ASX - By Stock
- RHS
- Ann: RHS Investor Presentation May 2017
Ann: RHS Investor Presentation May 2017, page-10
-
- There are more pages in this discussion • 15 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RHS (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
AHK
ARK MINES LIMITED
Ben Emery, Executive Director
Ben Emery
Executive Director
SPONSORED BY The Market Online